Value-Based HIV Formularies: Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care

Over the last 3 decades, ongoing advances in antiretroviral therapy (ART) for patients infected with human immunodeficiency virus (HIV) have improved outcomes across a diverse range of cohorts and clinical circumstances .1,2 As new data comparing existing drug regimens are published and new medications become available, HIV formularies must be periodically reviewed and adjusted to reflect both the evolving clinical evidence and various nonclinical parameters.3 Broad-based pharmacoeconomic assessment strategies should be used to optimize pharmacy-management practices within a value-based paradigm.4,5 In recognition of the needs of a multidisciplinary audience of HIV-formulary decision-makers, this webinar will bring together an expert faculty panel to review the latest clinical evidence for ART, available pharmacoeconomic data and their associated analytic instruments, and other key factors that can influence formulary changes and healthcare utilization. With an overall goal of improving HIV formularies, this educational program will help learners understand and address the complex relationships among healthcare cost, quality, and utilization.

References
1. Jones J, et al. CROI 2017: Advances in antiretroviral therapy. Top Antivir Med. 2017;25(2): 51-67.
2. DHHS. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed September 29, 2017.
3. Vogenberg FR et al. Systemic market and organizational changes: Impact on P&T committees. P & T 2017;42(1):28-32.
4. Fischer KE, et al. Link between process and appraisal in coverage decisions: An analysis with structural equation modeling. Med Decis Making. 2013;33(8):1009-1025.
5. Malone DC. The role of pharmacoeconomic modeling in evidence-based and value-based formulary guidelines. J Manag Care Pharm. 2005;11(4 Suppl):S7-S10.